Trinity Biotech

Trinity Biotech Book Value Growth

The Book Value Growth of Trinity Biotech (TRIB) as of Nov 10, 2026 is -104.60 %. In the previous year, Book Value Growth was -46.90 % — a change of 123.04% (lower).

Book Value Growth

-104.60 %

YoY

123.04%

Last updated:

Book Value Growth of Trinity Biotech is 2025 -104.60 % . Book Value Growth of Trinity Biotech was 2024 -46.90 % . It decreases by 123.04% lower compared to the previous year.

The Trinity Biotech Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2018
-32.43 USD
Jan 1, 2019
-89.30 USD
Jan 1, 2020
-147.08 USD
Jan 1, 2021
85.62 USD
Jan 1, 2022
-582.13 USD
Jan 1, 2023
-1,000.60 USD
Jan 1, 2024
-46.90 USD
Jan 1, 2025
-104.60 USD
The Trinity Biotech Book Value Growth history
YEARBook Value GrowthYoY
-104.60 %+123.04%
-46.90 %-95.31%
-1,000.60 %+71.89%
-582.13 %-779.87%
85.62 %-158.22%
-147.08 %+64.70%
-89.30 %+175.38%
-32.43 %-19.00%
-40.04 %-18.57%
-49.17 %-672.61%
8.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Book Value Growth of Trinity Biotech is -104.60 % in 2025.

On Eulerpool you can find the complete historical development of Book Value Growth Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Trinity Biotech

All Key Metrics — Trinity Biotech